Related by context. Frequent words. (Click for all words.) 61 NYSE MDT 59 Inc. NYSE STJ 58 Company NYSE BMY 56 NYSE BSX 56 NASDAQ CELG 55 Inc. Nasdaq EXEL 55 NASDAQ BPAX 55 Nasdaq VRTX 55 NYSE GDT 54 Corp. BSX 54 Inc. Nasdaq HGSI 54 NYSE ELN 54 Company NASDAQ MDCO 54 Inc. NYSE FRX 53 Ltd. NASDAQ TEVA 53 multicenter clinical 53 Inc. NASDAQ ILMN 53 NASDAQ ARIA 53 NYSE AGN 53 Phase 2b clinical 53 SPIRIT III 53 CTI Nasdaq 52 Nasdaq ISIS 52 Spectranetics Corporation 52 Inc. Nasdaq SGEN 52 Idera Pharmaceuticals Inc. 52 Nasdaq ALTR 52 label multicenter 52 TSX ANP 52 phase IIa 52 NYSE PFE 52 OTCQX RHHBY 52 Inc. NASDAQ ALKS 52 Inc. Nasdaq AFFX 51 Inc. Nasdaq CEPH 51 Inc. Nasdaq XLNX 51 Phase IIa clinical 51 Phase 1b clinical 51 Nymox Pharmaceutical Corporation 51 Ltd. Nasdaq TEVA 51 Phase III pivotal 51 Corporation NYSE SGP 51 Covidien NYSE COV 51 Transcatheter Cardiovascular Therapeutics TCT 51 Nasdaq GERN 51 NYSE AZN 50 Oscient Pharmaceuticals Corporation 50 Phase 2a clinical 50 Nasdaq GILD 50 EuroPCR 50 Wyeth NYSE WYE 50 Inc. NYSE PFE 50 Medical NYSE STJ 49 Phase IIb clinical 49 ARIAD Pharmaceuticals Inc. 49 Inc. NYSE WLP 49 EpiCept Corporation 49 CYPHER ® Stent 49 Stent System 49 Sunesis Pharmaceuticals Inc. 49 ZIOPHARM Oncology Inc. 49 Phase III clinical 49 Ligand Pharmaceuticals Incorporated 49 Inc. NASDAQ CLDA 49 NYSE ABT 49 MGI PHARMA INC. 49 pivotal Phase III 49 NYSE ORB 49 Vertex Pharmaceuticals Incorporated 49 NASDAQ AMGN 49 NYSE KCI 49 TAXUS R 49 Inc. NYSE TLB 49 confirmatory Phase III 48 Dynavax Technologies Corporation 48 Phase IIa trial 48 Inc. Nasdaq NVAX 48 Investigational Device Exemption IDE 48 Rexahn Pharmaceuticals 48 Amgen NASDAQ AMGN 48 ALTH 48 DCTH 48 Inc. NYSE AEO 48 NYSE RHB 48 NYSE HLS 48 Adolor Corporation 48 clinical trial 48 placebo controlled clinical 48 Protalix BioTherapeutics Inc. 48 NASDAQ CRXL 48 Biogen Idec NASDAQ BIIB 48 ADVENTRX Pharmaceuticals Inc. 48 Anika Therapeutics Inc. 48 Keryx Biopharmaceuticals Inc. 48 Board DSMB 47 Alexza Pharmaceuticals Inc. 47 TAXUS stent 47 phase 2a 47 Pharmion Corporation 47 NYSE SNN 47 Phase IIa